UCB suffers as cold weather delays hay fever season
BRUSSELS, April 25
BRUSSELS, April 25 (Reuters) - Belgian drugmaker UCB had a difficult first quarter as cold spring weather in Europe meant fewer hay fever sufferers were buying its allergy medicines, it said on Thursday.
Its revenues for the quarter slipped 9 percent to 799 million euros ($1.04 billion) impacted by slower sales of its allergy drugs Xyzal and Zyrtec, and as generic competition continues to eat into its former blockbuster Keppra, an epilepsy treatment.
It said Keppra sales fell 23 percent, but reiterated its full-year guidance for revenue of about 3.4 billion euros as its new range of drugs continue to pick up the slack.
($1 = 0.7695 euros) (Reporting By Ben Deighton, Editing By Ethan Bilby)
- Three dead, two wounded in Pasadena, California shootings
- Israeli commandos clash with Hamas gunmen in Gaza raid |
- Teen survivor of Texas shootings says slain family members 'in much better place'
- Rape and murder of 13-year-old spark debate in junta-ruled Thailand
- Israeli commandos clash with Hamas gunmen in Gaza raid